Journal: Rheumatol Int. 2006 Oct 13; [E-publication ahead of print] Authors and affiliation: Calandre EP, Hidalgo J, Rico-Villademoros F. Instituto de Neurociencias, Universidad de Granada, Avenida de Madrid 11, 18012, Granada, Spain, firstname.lastname@example.org. PMID: 17039363
Atypical antipsychotics may be useful in chronic pain treatment.
The objective of the present study was to assess the effect of ziprasidone in Fibromyalgia management. Ziprasidone was administered to 32 fibromyalgia patients at a dose of 20 mg/day, subsequently adjusted according to clinical response and tolerability. Fibromyalgia Impact Questionnaire (FIQ), Pittsburgh Sleep Quality Index (PSQI), a Clinical Global Impression improvement scale (CGIi), and a scale evaluating the severity of fibromyalgia symptoms were administered at 4 week intervals for 12 weeks. Drug adverse reactions were recorded.
Ten patients withdrew from the study. The CGIi showed 32% of responders. FIQ and PSQI scores showed a non-statistically significant decrease. The conditions of stiffness, anxiety and sadness improved significantly. Most frequent side effects included sleep disturbances, headache, tremor, and rigidity.
Although ziprasidone does not seem an especially useful adjunct drug in Fibromyalgia, it could be tried on patients who are markedly anxious and/or depressed.